104 related articles for article (PubMed ID: 7545144)
1. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma.
Riedl S; Bodenmüller H; Hinz U; Holle R; Möller P; Schlag P; Herfarth C; Faissner A
Int J Cancer; 1995 Feb; 64(1):65-9. PubMed ID: 7545144
[TBL] [Abstract][Full Text] [Related]
2. Tenascin-C in serum: a questionable tumor marker.
Schenk S; Muser J; Vollmer G; Chiquet-Ehrismann R
Int J Cancer; 1995 May; 61(4):443-9. PubMed ID: 7538974
[TBL] [Abstract][Full Text] [Related]
3. Serum tenascin levels in chronic liver disease.
Yamauchi M; Mizuhara Y; Maezawa Y; Toda G
Liver; 1994 Jun; 14(3):148-53. PubMed ID: 7521506
[TBL] [Abstract][Full Text] [Related]
4. Tenascin-C in serum: an acute-phase protein or a carcinoma marker?
Schenk S; Muser J; Vollmer G; Chiquet-Ehrismann R
Int J Cancer; 1995 Jan; 60(1):145. PubMed ID: 7529210
[No Abstract] [Full Text] [Related]
5. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.
Takeda A; Otani Y; Iseki H; Takeuchi H; Aikawa K; Tabuchi S; Shinozuka N; Saeki T; Okazaki Y; Koyama I
World J Surg; 2007 Feb; 31(2):388-94. PubMed ID: 17219282
[TBL] [Abstract][Full Text] [Related]
6. Identification of mannose receptor and CD163 as novel biomarkers for colorectal cancer.
Ding D; Yao Y; Yang C; Zhang S
Cancer Biomark; 2018 Feb; 21(3):689-700. PubMed ID: 29226859
[TBL] [Abstract][Full Text] [Related]
7. Development and application of an enzyme immunoassay for tenascin.
Washizu K; Kimura S; Hiraiwa H; Matsunaga K; Kuwabara M; Ariyoshi Y; Kato K; Takeuchi K
Clin Chim Acta; 1993 Oct; 219(1-2):15-22. PubMed ID: 7508343
[TBL] [Abstract][Full Text] [Related]
8. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum placenta growth factor level as a new marker for stage II or III colorectal cancer patients.
Kemık O; Sarbay Kemık A; Sümer A; Purısa S; Tükenmez B; Tüzün S
Turk J Gastroenterol; 2012 Apr; 23(2):104-9. PubMed ID: 22706737
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics.
Mourtzikou A; Stamouli M; Kroupis C; Christodoulou S; Skondra M; Kastania A; Pectasides D; Athanasas G; Dimas C
Clin Lab; 2012; 58(5-6):441-8. PubMed ID: 22783573
[TBL] [Abstract][Full Text] [Related]
12. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
13. Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study.
Al-Shuneigat JM; Mahgoub SS; Huq F
J Biomed Sci; 2011 Jul; 18(1):50. PubMed ID: 21787404
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
16. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer.
Chang YT; Huang MY; Yeh YS; Huang CW; Tsai HL; Cheng TL; Wang JY
PLoS One; 2016; 11(10):e0163264. PubMed ID: 27701415
[TBL] [Abstract][Full Text] [Related]
18. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
[TBL] [Abstract][Full Text] [Related]
19. CEA and relapse after the operation of colorectal carcinoma.
Pribelsky M; Pechan J; Krizan M; Pindak D
Bratisl Lek Listy; 2002; 103(11):428-31. PubMed ID: 12585359
[TBL] [Abstract][Full Text] [Related]
20. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
